Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome
- 96 Downloads
Antidepressants are used in irritable bowel syndrome (IBS) and may have effects on the gut independent of improving mood. We have investigated the actions of a tricyclic antidepressant on small intestinal motor function in eight healthy volunteers and in six patients with diarrhea-predominant IBS. Fasting ambulatory motility was recorded from six small intestinal sites for 16–18 hr while on no drug (baseline) and while taking imipramine for five days. Orocecal transit time (OCTT) was measured by lactulose hydrogen breath test, during baseline and imipramine administration. Imipramine did not alter migrating motor complex periodicity, but slowed jejunal phase III propagation velocity in controls from 7.5±1.1 to 3.6±0.5 cm/min (P<0.01) and in IBS from 7.8±0.6 to 4.4±0.5 cm/min (P<0.0001). Phase III duration at each site was increased, and total recorded phase III was greater during imipramine than baseline studies. Imipramine increased the amplitude of phase III contractions. There was no effect of imipramine on non-phase-III motility index or discrete clustered contractions. Imipramine prolonged OCTT from 73±6 min to 97±8 min in controls (P<0.05) and from 61±9 min to 89±8 min in IBS (P<0.05). Although OCTT was shorter in this IBS group, no motility differences were seen between controls and IBS. This demonstration that a tricyclic antidepressant can modify small intestinal motor function in health and in IBS supports the view that these drugs may have therapeutic actions in IBS unrelated to mood improvement.
Key wordsmotility antidepressant intestine imipramine irritable bowel syndrome transit
Unable to display preview. Download preview PDF.
- 15.Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W: Irritable bowel syndrome: Guidelines for the diagnosis. Gastroenterol Int 2:92–95, 1989Google Scholar
- 21.Misiewicz JJ, Waller SL, Eisner M: Motor respones of human gastrointestinal tract to 5-hydroxytryptaminein vivo andin vitro. Gut 7:208–216, 1966Google Scholar
- 23.Thollander M, Hellström PM, Svensson TH: Suppression of migrating motor complexes in human small intestine by alpha2-adrenoceptor agonist oxymetazoline. Gastroenterology 102:A526, 1992Google Scholar
- 27.Thompson DG, Wingate DL: Oral hyoscine butylbromide does not alter the pattern of small intestinal motor activity. Br J Pharmacol 723:685–687, 1981Google Scholar
- 30.Lederer PC, Thiemann R, Femppel J, Domschke W, Lux G: Influence of atropine, pirenzepine and cimetidine on nocturnal gastrointestinal motility and gastric acid secretion. Scand J Gastroenterol 17(suppl 72):131–137, 1982Google Scholar
- 31.Hills JM, Chau SP: A comparison of the inhibitory activity of mebeverine (musculotropic) with chlordiazepoxide (anxiolytic) and desipramine (antidepressant) in guinea-pig intestine. Br J Pharmacol 108:172P, 1993Google Scholar
- 36.Diamond S: Amitriptyline in the treatment of gastrointestinal disorders. Psychosomatics 5:221–224, 1964Google Scholar